FDA is­sues draft guid­ance on NASH drug de­vel­op­ment

The FDA on Mon­day is­sued draft guid­ance on de­vel­op­ing drugs to treat pa­tients who have non­cir­rhot­ic non­al­co­holic steato­hep­ati­tis (NASH) with liv­er fi­bro­sis.

“Cur­rent­ly, there are no ap­proved drugs for the treat­ment of NASH. Giv­en the high preva­lence of NASH, the as­so­ci­at­ed mor­bid­i­ty, the grow­ing bur­den of end-stage liv­er dis­ease, and the lim­it­ed avail­abil­i­ty of liv­ers for or­gan trans­plan­ta­tion, FDA be­lieves that iden­ti­fy­ing ther­a­pies that will slow the progress or, halt, or re­verse NASH and NAFLD will ad­dress an un­met med­ical need,” FDA writes.

How­ev­er, FDA ac­knowl­edges that there are knowl­edge gaps that present chal­lenges to de­vel­op­ing drugs to treat NASH. One par­tic­u­lar chal­lenge is that there are cur­rent­ly no cri­te­ria for iden­ti­fy­ing which pa­tients with non­al­co­holic fat­ty liv­er (NAFL) will progress to NASH.

Be­cause of this, FDA says that spon­sors should fo­cus on de­vel­op­ing treat­ments non­cir­rhot­ic NASH with liv­er fi­bro­sis un­til there are meth­ods for iden­ti­fy­ing the sub­set of pa­tients who are at risk of pro­gres­sion.

FDA al­so en­cour­ages spon­sors to de­vel­op and val­i­date bio­mark­ers for di­ag­nos­ing and grad­ing NASH and liv­er fi­bro­sis, as liv­er biop­sy is cur­rent­ly the on­ly re­li­able method for di­ag­nos­ing the dis­ease.

Guid­ance

The guid­ance it­self pro­vides rec­om­men­da­tions for pre­clin­i­cal and clin­i­cal de­vel­op­ment as well as tri­al de­sign and end­point se­lec­tion to sup­port ap­proval of drugs to treat non­cir­rhot­ic NASH with liv­er fi­bro­sis.

FDA notes that the guid­ance is not meant to cov­er the de­vel­op­ment of drugs to treat cir­rho­sis caused by NASH or the de­vel­op­ment of in vit­ro di­ag­nos­tics that may be used in de­vel­op­ing drugs to treat the dis­ease.

For Phase 3 stud­ies, FDA says that spon­sors should en­roll pa­tients with a his­to­log­i­cal di­ag­no­sis of NASH with liv­er fi­bro­sis made with­in six months of en­roll­ment, tak­ing in­to con­sid­er­a­tion pa­tients’ stan­dard of care and back­ground ther­a­py for oth­er chron­ic con­di­tions. FDA al­so says that pa­tients’ weight should be sta­ble for three months pri­or to en­roll­ment.

FDA al­so says that Phase 3 stud­ies for NASH should be dou­ble-blind and place­bo-con­trolled with the goal of slow­ing, halt­ing or re­vers­ing dis­ease pro­gres­sion and im­prov­ing clin­i­cal out­comes.

“Be­cause of the slow pro­gres­sion of NASH and the time re­quired to con­duct a tri­al that would eval­u­ate clin­i­cal end­points such as pro­gres­sion to cir­rho­sis or sur­vival, the FDA rec­om­mends spon­sors con­sid­er … liv­er his­to­log­i­cal im­prove­ments as end­points rea­son­ably like­ly to pre­dict clin­i­cal ben­e­fit to sup­port ac­cel­er­at­ed ap­proval,” FDA writes.

Those end­points in­clude res­o­lu­tion of steato­hep­ati­tis on over­all histopatho­log­i­cal read­ing and no wors­en­ing of liv­er fi­bro­sis on NASH Clin­i­cal Re­search Net­work (CRN) fi­bro­sis score and/or im­prove­ment in liv­er fi­bro­sis greater than or equal to one stage (NASH CRN fi­bro­sis score) and no wors­en­ing of steato­hep­ati­tis.

For NASH treat­ments grant­ed ac­cel­er­at­ed ap­proval on the ba­sis of liv­er his­tol­ogy, FDA says that ran­dom­ized, dou­ble-blind, place­bo-con­trolled tri­als to ver­i­fy clin­i­cal ben­e­fits should be un­der­way when the mar­ket­ing ap­pli­ca­tion is sub­mit­ted.

The guid­ance al­so pro­vides some caveats for pe­di­atric de­vel­op­ment, as “Pe­di­atric NASH ap­pears to have dif­fer­ent his­to­log­i­cal char­ac­ter­is­tics as well as a dif­fer­ent nat­ur­al his­to­ry when com­pared to adult NASH. For rea­sons that are cur­rent­ly un­known, dis­ease char­ac­ter­is­tics and pro­gres­sion in pe­di­atric pa­tients may be dif­fer­ent.”

As such, FDA says that ex­trap­o­la­tion of ef­fi­ca­cy from adults “is not ap­pro­pri­ate at this time,” and that lon­gi­tu­di­nal nat­ur­al his­to­ry da­ta for pe­di­atric pa­tients are need­ed.

FDA says it plans to fur­ther ad­dress is­sues re­lat­ed to pe­di­atric non­cir­rhot­ic NASH in an up­com­ing guid­ance.

Draft Guid­ance, Fed­er­al Reg­is­ter No­tice


First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

From left to right: Lilian Kim, Associate Director Business Development; John Moller, CEO; Yooni Kim, Executive Director, Asia Operations; Michelle Park, Director South Korea Operations.

Novotech CRO sees 26% growth in Asia tri­al ac­tiv­i­ty from biotechs, but still plen­ty of ca­pac­i­ty

As the Asia-Pacific clinical trials sector continues to grow rapidly, Novotech the Asia-Pacific-based CRO is seeing biotech clinical activity up by 26%. But says there is still plenty of capacity in the region that features advanced medical facilities, supportive regulatory environments, and more than 2.3 billion people, largely treatment naïve, living in urban areas.

China, South Korea and Australia have the most studies registered as recruiting or about to recruit according to ClinicalTrials.Gov.

A preda­tor's world? Top an­a­lyst sees the 'haves' and the 'haven't­s' di­verge as biotech bub­bles form — and col­lapse

Josh Schimmer

We’ve all seen the deluge of cash that’s been pouring into biotech from every angle: VCs, IPOs and follow-ons have generated billions in capital for new and emerging drug developers with ready access to some powerful new tech. But Evercore ISI’s Josh Schimmer is asking where we’re headed from here.

His answer is neither apocalyptic nor universally blissful, but if he’s right — and this is a discussion we’re hearing much, much more about at a time of growing economic and industry uncertainty — we may well be at a crossroads that could affect valuations, M&A and the entire global industry that has formed over the past 5 years.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

Pfizer, South San Francisco — Jeff Rumans for Endpoints News

UP­DAT­ED: Pfiz­er takes aim at a flag­ship fran­chise at Sanofi and Re­gen­eron — and scores a few di­rect hits

Count Pfizer in as a top player in the blockbuster game of JAK1 inhibitors.

Over the weekend the pharma giant posted some stellar Phase III efficacy data for their heavyweight contender abrocitinib in atopic dermatitis (eczema) that lines up ahead of a booming Dupixent (dupilumab), a blockbuster in the portfolios of Regeneron and Sanofi. And they put some real distance ahead of Eli Lilly’s trailing Olumiant, which made a delayed initial arrival on the market for rheumatoid arthritis after the FDA hobbled it with some additional hurdles on safety concerns.

JADE-MONO-1 scores well for Pfizer, teeing up what will be an intensely followed breakdown of the JADE MONO-2 data, which the pharma giant recently top-lined as “similar” to the first Phase III when tested against a placebo — a control group that has been easily outclassed by all the drugs in this market niche.

As of now, Pfizer looks to be equipped to run into the review stage — advantaged by a breakthrough therapy designation that is intended to speed up the regulatory process.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

Cell ther­a­py start­up rais­es $16 mil­lion to fund its quest for the Holy Grail in re­gen­er­a­tive med­i­cine

In 2006, Shinya Yamanaka shook stem cell research with his discovery that mature cells can be converted into stem cells, relieving a longstanding political-ethical blockage and throwing open medical research on everything from curbing eye degeneration to organ printing.

But that process still has pitfalls, including in risk and scalability, and some researchers are exploring another way first hinted at years ago: new technology to convert mature cells directly into other mature cells without the complex and time-consuming process of first making them into stem cells.

Eye­ing $86M, Galera leads a pack of three mod­est biotech IPOs push­ing past high pro­file stum­bles

Exactly one year after kicking off a pivotal Phase III study for its lead drug — a companion for cancer patients receiving radiotherapy — Galera is looking to the Nasdaq for some new cash to complete the clinical work and fuel its commercial drive.

CEO Mel Sorensen has penciled in an $86 million ask, which was filed on the same day as liver disease company 89bio and rare disease diagnostics shop Centogene. The trio marks the first batch of IPO filings in the wake of two highly anticipated but ultimately disappointing public debuts by BioNTech and Vir, signaling dwindling biotech fervor on Wall Street. 89bio and Centogene are seeking $70 million and $69 million, respectively.

Pelosi drug pric­ing bill promis­es sav­ings, but could gag R&D — CBO analy­sis

The Democrats’ drug pricing bill — unveiled by Speaker Nancy Pelosi last month — could save Medicare spending by $345 billion over a seven year period, a new analysis suggests. But the venomous climate of impeachment proceedings and the intensifying discord between the Democrat-controlled House and Republican-majority Senate portends the bill will unlikely ever become law.

Technically, both sides of the aisle agree drug prices in the United States need some lowering. The Democrats’ bill, H.R.3 – Lower Drug Costs Now Act of 2019, is engineered to empower the HHS to negotiate prices for the 125 most expensive prescription drugs without at least two competitors — the Trump administration has already backed such a measure for the Veterans Association. Under the bill, prices for this category of medicines are not intended to exceed 120% of the average price in certain other countries (Australia, Canada, France, Germany and the United Kingdom), akin to a proposal floated by Trump earlier this year, which suggested prices be pegged against what other nations were paying as part of an “international pricing index”.

Hal Barron and Rick Klausner (GSK, Lyell)

Ex­clu­sive: GSK’s Hal Bar­ron al­lies with Rick Klaus­ner’s $600M cell ther­a­py start­up, look­ing to break new ground blitz­ing sol­id tu­mors

LONDON — Chances are, you’ve heard little or nothing about Rick Klausner’s startup Lyell. But that ends now.

Klausner, the former head of the National Cancer Institute, former executive director for global health at the Gates Foundation, co-founder at Juno and one of the leaders in the booming cell therapy field, has brought together one of the most prominent teams of scientists tackling cell therapy 2.0 — highlighted by a quest to bridge a daunting tech gap that separates some profound advances in blood cancers with solid tumors. And today he’s officially adding Hal Barron and GlaxoSmithKline as a major league collaborator which is pitching in a large portion of the $600 million he’s raised in the past year to make that vision a reality.

“We’ve being staying stealth,” Klausner tells me, then adding with a chuckle: “and going back to stealth after this.”

“Cell therapy has a lot of challenges,” notes Barron, the R&D chief at GSK, ticking off the resistance put up by solid tumors to cell therapies, the vein-to-vein time involved in taking immune cells out of patients, engineering them to attack cancer cells, and getting them back in, and more. “Over the years Rick and I talked about how it would be wonderful to take that on as a mission.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

First place fin­ish: Eli Lil­ly just moved to fran­chise leader with their sec­ond mi­graine drug OK in 1 year

In a rare twist for Eli Lilly’s historically slow-moving R&D group, the pharma giant has seized bragging rights to a first-in-class new drug approval. And all signs point to an aggressive marketing followup as they look to outclass some major franchise rivals hobbled by internal dissension.

The FDA came through with an OK for lasmiditan on Friday evening, branding it as Reyvow and lining it up — once a substance classification comes through from the DEA — for a major market release. The oral drug binds to 5-HT1F receptors and is designed to stop an acute migraine after it starts. That makes it a complementary therapy to their CGRP drug Emgality, which has a statistically significant impact on preventing attacks.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,000+ biopharma pros reading Endpoints daily — and it's free.

Patrick Mahaffy, Getty Images

Court green-lights Clo­vis case af­ter de­tail­ing ev­i­dence the board ‘ig­nored red flags’ on false safe­ty and ef­fi­ca­cy da­ta

Clovis investors have cleared a major hurdle in their long-running case against the board of directors, with a Delaware court making a rare finding that they had a strong enough case against the board to proceed with the action.

In a detailed ruling at the beginning of the month that’s been getting careful scrutiny at firms specializing in biotech and corporate governance, the Delaware Court of Chancery found that the attorneys for the investors had made a careful case that the board — a collection of experts that includes high-profile biotech entrepreneurs, a Harvard professor and well-known investigator as well as Clovis CEO Patrick Mahaffy — repeatedly ignored obvious warnings that Mahaffy’s executive crew was touting inflated, unconfirmed data for their big drug Roci. Serious safety issues were also reportedly overlooked while the company continued a fundraising campaign that brought in more than a half-billion dollars. And that leaves the board open to claims related to their role in the fiasco.

The bottom line:

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.